EfficacyBarzolvolimab's efficacy continues to impress in the treatment of angioedema with an 86% mean reduction from baseline in AAS7 for patients.
Market OpportunityBarzolvolimab’s unique mast cell-depleting mechanism offers a differentiated, first-in-class profile that stands to unlock significant commercial opportunity in urticaria and other mast cell-driven diseases.
Safety ProfileBarzolvolimab administration is safe and well tolerated with side effects reported as rare, mild, and reversible.